Medical Health & Life Science Research News

Explore refractory chronic lymphocytic leukemia global market analysis H2 2016

Pharmaceutical and Healthcare latest pipeline guide Refractory Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The report provides comprehensive information on the therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report provides an overview of key players involved in therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL)   and features dormant and discontinued projects.              

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

- Advertising -

- Agency -

Complete report on Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016 addition with 51 market data tables and 14 figures, spread across 266 pages is available at www.reportsnreports.com/reports/764550-refractory-chronic-lymphocytic-leukemia-cll-pipeline-review-h2-2016.html

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, Investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis

Drug Profile Discussed /Mentioned in this Research:

dezapelisib + itacitinib adipate, acalabrutinib, ACP-319, afuresertib hydrochloride, AGS-67E, AR-42, AT-7519, atezolizumab, BI-836826, BMS-986016, buparlisib hydrochloride, CBM-C19.1, CBM-C20.1, CC-122, Cellular Immunotherapy for Chronic Lymphocytic Leukaemia, cerdulatinib, duvelisib, HMPL-523,v, IMGN-529, IMMU-114, JCAR-014, JCAR-015, lirilumab, MDNA-56, monalizumab, MOR-208, nivolumab, obinutuzumab PCAR-019, pilaralisib, selinexor, spebrutinib besylate, tisagenlecleucel-T, ulocuplumab, urelumab

Companies Discussed /Mentioned in this Research:

AbbVie Inc, Arno Therapeutics,Astellas Pharma Inc.,Astex Pharmaceuticals Inc,Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Cellular Biomedicine Group, F. Hoffmann-La Roche Ltd., Gilead Sciences, Hutchison MediPharma Limited, ImmunoGen, Immunomedics, Incyte Corporation, Innate Pharma S.A., Juno Therapeutics Inc., Karyopharm Therapeutics, LFB S.A., Lymphocyte Activation Technologies, Medicenna Therapeutics, Inc., Millennium Pharmaceuticals Inc, MorphoSys AG, Novartis AG, Oncternal Therapeutics,

Inquire report www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=764550

Scope                                                                                                             

  • The report provides a snapshot of the global therapeutic landscape of Refractory Chronic Lymphocytic Leukemia (CLL)
  • The report reviews pipeline therapeutics for Refractory Chronic Lymphocytic Leukemia (CLL) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Refractory Chronic Lymphocytic Leukemia (CLL)  therapeutics and enlists all their major and minor projects
  • The report assesses Refractory Chronic Lymphocytic Leukemia (CLL)  therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Refractory Chronic Lymphocytic Leukemia (CLL)

Reasons to acces

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL)    pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
...